NCT05552976

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 606 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

Conditions

• Relapsed or Refractory Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Mezigdomide	Specified dose on specified days
DRUG	Carfilzomib	Specified dose on specified days
DRUG	Dexamethasone	Specified dose on specified days

Timeline

• Start date: 2023-01-10
• Primary completion: 2026-07-18
• Completion: 2029-07-25
• First posted: 2022-09-23
• Last updated: 2026-04-01

Locations

207 sites across 27 countries: United States, Argentina, Australia, Austria, Brazil, Bulgaria, Canada, China, Colombia, Denmark, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Netherlands, Norway, Puerto Rico, Romania, Singapore, South Korea, Spain, Taiwan, United Kingdom

Regulatory

• FDA-regulated drug study